To Whom IT May Concern: Testing results: This is to confirm that the anti-microbial compound labeled as 2915-1916141125 has an efficacy of >99.99% percent on application to live virus. Application of compound labeled 2915-191?141125 has a continued efficacy at preventing the virus species from surviving on treated surface. Additionally compounds 2915-1916141125 and 2915-1916141-1612211960 have shown efficacy against norovirus, rotavirus, adenovirus,and poliovirus which are listed in the latest EPA document as surrogate species for success against Ebolavirus. (see attachment). See results excerpted below. TABLE I Viral Recoveries lind LogjQ and Pereent Reductio ... Followh11 Exposure to Telt Product #1, Nonwoven Treated Bille Material, and Test Product #3, Nonwoven Control Blue Material Virus: Swine-lib Influenza A HI Nl strai n AJCalifolnlalO4t2(l09 (CDC #200(712041) Hosl Coil Line: MOCK (ATCC IICCL-34) Volume PJ.ted pet Woll: 1.0 rnL Nonwoven Treated Blue Material Replicate 3 Replicate I Replicate 2 Dilation Plated Nonwoven Control Blue Moteriol Replicate I Replicate 2 Replicate 3 Jnfl!al Population -2 CT CT CT ++++ ++++ ++++ NT -3 +0++ 0000 0000 ++++ ++++ +++ ... ++++ ·4 ++00 0000 0000 ++++ ++++ ++++ ++++ -s 0000 0000 0000 ++++ ++++ +++ ... +H+ ·6 0000 0000 0000 +++0 ++00 ++0+ ++++ ·7 NT 3.75 NT NT 6.00 NT 6.25 H(}+ 2.50 NT 6.2~ NT 2.50 rcnx, 7.2! (log10) Avctllgo TCIO (loglo) 2.9;t ii,17 Average Loglo reduction 4.;l3 ).OS Average >99.99 91.68 Percent Reduction + - ePE present . o - CPE not detected CT· NT N/A- Cytoloxlcity Not tested Not applicable Dr. Ming Ph.D (Baylor University) Consulting Chemist. NA Interim Guidance for Environmental Infection Control in Hospitals for Ebola Virus: On August 1, 2014, CDCreleased guidance titled,"lnfection Prevention and Control Recommendations for Hospitalized Patients with Known or Suspected Ebala Hemorrhagic Fever in U.S. Hospitals." • • Use a U.S. Environmental Protection Agency (EPA)-registered hospital disinfectant with a label claim for a non-enveloped virus [e.g., norovirus, rotavirus, adenovirus, poliovirus) to disinfect environmental surfaces in rooms of patients with suspected or confirmed Ebola virus infection. Although there are no products with specific label claims against the Ebola virus, enveloped viruses such as Ebola are susceptible to a broad range of hospital disinfectants used to disinfect hard, non-porous surfaces. In contrast, non-enveloped viruses are more resistant to disinfectants. As a precaution, selection of a disinfectant product with a higher potency than what is normally required for an enveloped virus is being recommended at this time. EPAregistered hospital disinfectants with label claims against non-enveloped viruses (e.g., norovirus, rotavirus, adenovirus, poliovirus) are broadly antiviral and capable of inactivating both enveloped and non-enveloped viruses. 2